QGENQIAGEN N.V.
Biological Products, (no Diagnostic Substances)
- Revenue
- $2.1B
- 5.7% YoY
- Operating margin
- 22.3%
- 351% YoY
- EBITDA
- $660M
- 119% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.2×
- $815M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear154% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear51% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyFired43% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.1B | $2.0B | $2.0B | $2.1B | 5.7% |
| Operating income | $630M | $531M | $410M | $98M | $466M | 377% |
| Net income | $513M | $423M | $341M | $84M | $425M | 408% |
| Operating cash flow | $639M | $715M | $459M | $674M | $654M | 2.9% |
| Capex | $190M | $129M | $150M | $167M | $201M | 20% |
| Stock-based comp | $38M | $50M | $47M | $44M | $50M | 16% |
| Buybacks | $100M | $0 | $0 | $292M | $280M | 4.1% |
| Dividends | — | — | $0 | $0 | $54M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.